Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.

British journal of cancer - 1 May 2018

Ma Rui, Xu Ling, Qu Xiujuan, Che Xiaofang, Zhang Ye, Fan Yibo, Li Ce, Guo Tianshu, Hou Kezuo, Hu Xuejun, Drew Lisa, Shen Minhui, Cheung Tony, Liu Yunpeng

Abstract excerpt

BACKGROUND: BRAF mutation is associated with poor clinical outcome of patients with malignant tumours, and mediates resistance to chemotherapy and targeted therapy. This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304. METHODS: Kinase activity was assessed by the AlphaScreen assay. Then, MTT assay, EdU assay,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caco-2 Cells
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Extracellular Signal-Regulated MAP Kinases

Share to HT29 Cells

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29755114
DOI: 10.1038/s41416-018-0086-x
PMCID: PMC5988692

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.PMID 29755114Read ↗

Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.Semantic proximity Read ↗

EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.Semantic proximity Read ↗

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationSemantic proximity Read ↗

E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.Semantic proximity Read ↗

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.Semantic proximity Read ↗

The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.Semantic proximity Read ↗

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.Semantic proximity Read ↗

The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cellsSemantic proximity Read ↗

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.Semantic proximity Read ↗

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.